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Transplantation for Adolescent and Young Adults
Compared with Children and Older Adults with Acute
Myeloid Leukemia
Navneet S. Majhail,1 Ruta Brazauskas,2 Anna Hassebroek,1 Christopher N. Bredeson,3
Theresa Hahn,4 Gregory A. Hale,5 Mary M. Horowitz,6 Hillard M. Lazarus,7
Richard T. Maziarz,8 William A. Wood,9 Susan K. Parsons,10 Steven Joffe,11
J. Douglas Rizzo,6 Stephanie J. Lee,12 Brandon M. Hayes-Lattin8Adolescents and young adults (AYAs) with cancer have not experienced improvements in survival to the
same extent as children and older adults. We compared outcomes among children (\15 years), AYAs
(15-40 years) and older adults (.40 years) receiving allogeneic hematopoietic cell transplant (HCT) for acute
myeloid leukemia (AML). Our cohort consisted of 900 children, 2,708 AYA, and 2,728 older adult recipients
of HLA-identical sibling or unrelated donor (URD) transplantation using myeloablative or reduced-intensity/
nonmyeloablative conditioning. Outcomes were assessed over three time periods (1980-1988, 1989-1997,
1998-2005) for siblings and two time periods (1989-1997, 1998-2005) for URD HCT. Analyses were strat-
ified by donor type. Results showed overall survival for AYAs using either siblings or URD improved over
time. Although children had better and older adults had worse survival compared with AYAs, improvements
in survival for AYAs did not lag behind those for children and older adults. After sibling donor HCT, 5-year
adjusted survival for the three time periods was 40%, 48%, and 53% for children, 35%, 41%, and 42% for AYAs,
and 22%, 30%, and 34% for older adults. Among URD HCT recipients, 5-year adjusted survival for the
two time periods was 38% and 37% for children, 24% and 28% for AYAs, and 19% and 23% for older adults.
Improvements in survival occurred because of a reduction in risk of treatment-related mortality. The risk of
relapse did not change over time. Improvements in survival among AYAs undergoing allogeneic HCT for AML
have paralleled those among children and older adults.
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Table 1. Characteristics of PatientsWho Received HLA-Identical Sibling Donor or Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in the
United States from 1980 to 2005
Characteristics
Children Adolescent and Young Adults Older Adults
1980-1988 1989-1997 1998-2005
P Value
1980-1988 1989-1997 1998-2005
P Value
1980-1988 1989-1997 1998-2005
P ValueN (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Number of patients 110 373 417 462 1,109 1,137 57 683 1,988
Number of centers 19 60 67 36 105 111 17 87 102
Male 51 (46) 209 (56) 229 (55) 230 (50) 605 (55) 610 (54) 36 (63) 360 (53) 1,068 (54)
Race/ethnicity .01 <.01 .09
White 90 (82) 299 (80) 293 (70) 414 (90) 940 (85) 936 (82) 48 (84) 617 (90) 1,809 (91)
Other 19 (16) 73 (20) 123 (29) 47 (10) 168 (16) 190 (19) 9 (6) 65 (10) 163 (8)
Missing 1 (1) 1 (<1) 1 (<1) 1 (<1) 1 (<1) 11 (1) 0 1 (<1) 16 (1)
Performance status score at HCT .90 <.01 <.01
<90 20 (18) 76 (20) 75 (18) 128 (28) 389 (35) 348 (31) 19 (33) 309 (45) 681 (34)
$90 87 (79) 294 (79) 307 (74) 323 (70) 708 (64) 691 (61) 36 (63) 370 (54) 1,093 (55)
Missing 3 (3) 3 (1) 35 (8) 11 (2) 12 (1) 98 (9) 2 (4) 4 (1) 214 (11)
Disease status at HCT <.01 <.01 <.01
CR1 69 (63) 169 (45) 163 (39) 263 (57) 401 (36) 397 (35) 24 (42) 203 (30) 764 (38)
CR2 19 (17) 67 (18) 134 (32) 52 (11) 198 (18) 275 (24) 6 (11) 94 (14) 380 (19)
Primary induction failure 5 (5) 53 (14) 42 (10) 48 (10) 151 (14) 156 (14) 9 (16) 133 (19) 331 (17)
Relapse 16 (15) 76 (20) 69 (17) 84 (18) 318 (29) 283 (25) 17 (30) 231 (34) 443 (22)
Other/missing 1 (<1) 8 (2) 9 (2) 15 (3) 41 (4) 26 (2) 1 (2) 22 (3) 70 (6)
Cytogenetic risk at diagnosis <.01 <.01 <.01
Good 7 (6) 30 (8) 34 (8) 21 (5) 83 (7) 78 (7) 4 (7) 28 (4) 87 (4)
Intermediate 23 (21) 185 (50) 240 (58) 111 (24) 457 (41) 703 (62) 18 (32) 353 (52) 1,217 (61)
Poor 3 (3) 60 (16) 79 (19) 26 (6) 140 (13) 193 (17) 5 (9) 96 (14) 408 (21)
Unknown 77 (70) 98 (26) 64 (15) 304 (66) 429 (39) 163 (14) 30 (53) 206 (30) 276 (14)
Time from diagnosis to HCT <.01 <.01 .12
<6 months 73 (66) 201 (54) 200 (48) 311 (67) 480 (43) 455 (40) 33 (58) 290 (42) 831 (42)
6-12 months 18 (16) 104 (28) 83 (20) 82 (18) 340 (31) 339 (30) 10 (18) 213 (31) 603 (30)
>12 months 19 (17) 66 (18) 134 (32) 69 (15) 288 (26) 339 (30) 14 (25) 178 (26) 549 (28)
Missing 0 2 (1) 0 0 1 (<1) 4 (<1) 0 2 (<1) 5 (<1)
Graft type <.01 <.01 <.01
Bone marrow 110 (100) 370 (99) 340 (82) 462 (100) 1,056 (95) 609 (54) 57 (100) 627 (92) 694 (35)
Peripheral blood 0 3 (1) 77 (18) 0 53 (5) 528 (46) 0 56 (8) 1,294 (65)
HLA match* <.01 <.01 <.01
HLA-identical sibling 110 171 (46) 86 (21) 462 604 (54) 221 (19) 57 421 (62) 553 (28)
Unrelated, well-matched 0 37 (10) 134 (32) 0 91 (8) 446 (39) 0 74 (11) 897 (45)
Unrelated, partially matched 0 72 (19) 116 (28) 0 206 (19) 318 (28) 0 111 (16) 382 (19)
Unrelated, mismatched 0 87 (23) 75 (18) 0 207 (19) 140 (12) 0 73 (11) 135 (7)
Missing 0 6 (2) 6 (1) 0 1 (<1) 12 (1) 0 4 (1) 21 (1)
Conditioning regimen .16 <.01 <.01
Myeloablative 109 (99) 354 (95) 387 (93) 453 (98) 1,051 (95) 944 (83) 56 (98) 657 (96) 1,145 (58)
RIC/NMA 1 (1) 19 (5) 19 (5) 9 (2) 58 (5) 161 (14) 1 (2) 25 (4) 776 (39)
Missing 0 0 11 (3) 0 0 32 (3) 0 1 (<1) 67 (3)
GVHD prophylaxis <.01 <.01 <.01
CSA + MTX ± other 14 (13) 193 (52) 207 (50) 58 (13) 576 (52) 445 (39) 8 (14) 350 (51) 550 (28)
CSA ± other (no MTX) 20 (18) 44 (12) 18 (4) 162 (35) 229 (21) 74 (7) 25 (44) 139 (20) 360 (18)
FK506 + MTX 0 6 (2) 66 (16) 0 60 (5) 370 (33) 0 39 (6) 669 (34)
MTX 74 (67) 36 (10) 12 (3) 178 (39) 33 (3) 9 (1) 8 (14) 12 (2) 11 (1)
T cell depletion 2 (2) 92 (25) 98 (24) 59 (13) 183 (17) 142 (12) 16 (28) 106 (16) 125 (6)
Other 0 2 (1) 16 (4) 5 (1) 28 (3) 97 (9) 0 37 (5) 273 (14)
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Biol Blood Marrow Transplant 18:861-873, 2012 863AML Outcomes for AYAs after allo-HCTinclude age-related differences in biology, socioeco-
nomic status, access to care, adherence tomedical plans,
participation rates in clinical trials, treatment in centers
experienced with the care of AYA patients, caregiver
availability, and other psychosocial issues [6].
Innovations in transplantation care since the 1980s
have led to incremental improvements in survival and
reduction of treatment-relatedmortality (TRM) among
hematopoietic cell transplantation (HCT) recipients
[7,8]. Whether improvements in transplantation
outcomes have occurred to the same degree across all
age groups, particularly AYAs, is not well known.
Using data from the Center for International Blood
and Marrow Transplant Research (CIBMTR), we
compared outcomes of children, AYAs, and older
adult recipients of allogeneic HCT for acute myeloid
leukemia (AML) to determine whether AYAs, have
experienced improvements in survival at rates that are
similar to their younger and older counterparts.METHODS
Data Source and Patients
The CIBMTR is a research affiliation of the Inter-
national Bone Marrow Transplant Registry and the
NationalMarrowDonorProgram (NMDP)established
in 2004, which comprises a voluntary working group of
more than 450 transplantation centers worldwide that
contribute detailed data on consecutive allogeneic and
autologous HCTs to a Statistical Center at theMedical
College of Wisconsin in Milwaukee and the NMDP
CoordinatingCenter inMinneapolis. Participating cen-
ters are required to report all transplantations consecu-
tively; compliance is monitored by on-site audits.
Patients are followed longitudinally, with yearly
follow-up.Computerized checks for discrepancies, phy-
sicians’ review of submitted data, and on-site audits of
participating centers ensure data quality. Observational
studies conducted by the CIBMTR are performed in
compliance with the Privacy Rule (HIPAA) as a Public
Health Authority and in compliance with all applicable
federal regulations pertaining to the protection of hu-
man research participants as determined by continuous
review of the institutional review board of the NMDP
and the Medical College of Wisconsin since 1985.
For this study, we included patients who had re-
ceived their first allogeneicHCT for AMLusing either
an HLA-identical sibling donor (matched sibling
donor, MSD) or unrelated donor (URD), from 1980
to 2005 at a US transplantation center. Patients
who underwent transplantation using myeloablative
reduced-intensity (RIC) or nonmyeloablative (NMA)
conditioning regimens were included in this analysis.
Patients with acute promyelocytic leukemia, recipients
of cord blood grafts, and recipients of prior autologous
HCT were excluded. Patients were divided into three
864 Biol Blood Marrow Transplant 18:861-873, 2012N. S. Majhail et al.groups based on age at transplantation: children
(\15 years), AYA (15-40 years) [2], and older adults
(.40 years).
All surviving recipients included in this analysis
were contacted retrospectively and provided informed
consent for participation in the NMDP research pro-
gram. Informed consent was waived by the NMDP
institutional review board for all deceased recipients.
Approximately 10% of surviving patients would not
provide consent for use of research data. To adjust
for the potential bias introduced by exclusion of non-
consenting surviving patients, a corrective actionmod-
eling process randomly excluded the same percentage
of deceased patients using a biased coin randomization
with exclusion probabilities based on characteristics
associated with not providing consent for use of the
data in survivors [9].
Outcomes and Study Definitions
The primary objective of this study was to compare
change over time in rates of overall survival (OS),
leukemia-free survival (LFS), relapse, and TRM
among children, AYAs, and older adults. For OS,
death from any cause was considered an event. LFS
was defined as survival in complete remission (CR) af-
ter HCT. Relapse was defined as leukemia recurrence.
TRM was defined as death in CR. All outcomes were
assessed from the date of transplantation.
Disease status was classified as early, intermediate,
or advanced [10]. Early disease included AML in CR1.
AML in $CR2 was categorized as intermediate, and
patients in relapse/primary induction failure were clas-
sified as having advanced disease. The NMDP classifi-
cation of HLA-matching status was used for URD
recipients (well-matched, partially matched, or mis-
matched) [11]. Conditioning regimens were classified
as myeloablative or RIC/NMA based on CIBMTR
definitions [12]. Where information was available, cy-
togenetic risk was classified according to standard cri-
teria as good, intermediate, or poor [13,14].
Statistical Methods
Summaries of patient-, disease-, and treatment-
related characteristics were produced for the three
age groups. Univariate probabilities of OS and LFS
were calculated using the Kaplan-Meier estimator
[15]. Probabilities of relapse and TRM were estimated
using a cumulative incidence function method [16].
Separate analyses were performed for MSD and
URD recipients. To evaluate changes in outcomes
over time, we divided the MSD cohort into three
time periods (1980-1988, 1989-1997, and 1998-
2005) based on the year of transplantation. Because
the NMDP began facilitating URD HCT in the
United States in 1986, the URD cohort was evaluated
over two time periods (1989-1997 and 1998-2005).Cox proportional hazards models were used to
adjust for significant covariates while comparing the
three age groups. All factors were examined for propor-
tional hazards using a time-dependent covariate
approach. The nonproportional hazards were addressed
by introducing a time-dependent covariate to appropri-
ately model early versus later events in OS (\3 months
and $3 months), relapse (\3 months and $3 months),
andTRM (\6months and$6months) inmultivariable
analyses for MSD recipients. A backward regression
model selection technique was used to identify signifi-
cant covariates to be included in the models. The main
effects tested in all multivariate analysis models for the
outcomes of interest were age and time period of trans-
plantation. Interaction between age and time period was
also examined. All P values were two-sided, and risk fac-
tors of P\ .05 were included in the finalmodel. In addi-
tion to age and time period of transplantation, the
covariates considered in the multivariable models in-
cluded gender, Karnofsky/Lansky performance status
at HCT (\90 versus $90), disease status at HCT
(CR1 versus CR2 versus other), time from diagnosis to
HCT (\6 versus 6-12 versus.12months), graft source
(peripheral blood versus bonemarrow), donor-recipient
gender mismatch, and donor-recipient cytomegalovirus
status. HLA matching status was also considered for
URD recipients. Transplantation practices such as use
conditioning regimen intensity and graft-versus-host
disease prophylaxis regimens changed at different rates
over time among the three age groups; hence, we did
not adjust for these variables in multivariate analyses.
All computations were performed using the SAS
Version9.2 statistical package (SASInstitute,Cary,NC).RESULTS
Patient Characteristics
Table 1 describes patient, disease, and transplanta-
tion characteristics. Overall, 900 children, 2,708 AYAs,
and 2,728 older adults met the study inclusion criteria.
The numbers of patients undergoing a transplantation
increased over time for all age groups. This increase
was largely because of greater utilization of URD
transplantations. Among URD recipients, a greater
proportion received HLA well-matched grafts in the
most recent time period. Other notable trends over
time included increasing utilization of peripheral
blood as a graft source (particularly among AYA and
older adult recipients) and larger numbers of older
adults undergoing RIC/NMA HCT.
Outcomes after HLA-Identical Sibling Donor
HCT
Univariate analysis showed that the probability of
OS at 5 years posttransplantation improved signifi-
cantly for patients who underwent transplantation
Table 2. Unadjusted Probability of Overall Survival and Leukemia-Free Survival and Cumulative Incidence of Relapse and
Treatment-Related Mortality at 5 Years after Transplantation
Outcome 1980-1988* 1989-1997* 1998-2005* P Value†
Matched sibling donor HCT
Overall survival .23
Children 45 (41-50)% 53 (49-57)% 64 (57-71)%
Adolescent and young adults 37 (35-39)% 40 (38-42)% 43 (40-46)%
Older adults 21 (19-23)% 26 (25-27)% 31 (30-33)%
Leukemia-free survival .76
Children 45 (36-55)% 47 (39-55)% 58 (47-69)%
Adolescent and young adults 35 (31-40)% 36 (32-40)% 42 (35-49)%
Older adults 20 (10-31)% 26 (22-30)% 29 (25-34)%
Relapse <.01
Children 32 (24-42)% 43 (35-50)% 26 (17-37)%
Adolescent and young adults 26 (22-30)% 34 (30-38)% 38 (31-45)%
Older adults 13 (5-23)% 31 (26-35)% 40 (36-44)%
Treatment-related mortality .01
Children 22 (15-31)% 10 (6-15)% 16 (8-25)%
Adolescent and young adults 39 (35-44)% 30 (26-34)% 20 (15-26)%
Older adults 67 (55-79)% 44 (39-48)% 31 (27-35)%
Unrelated donor HCT
Overall survival .87
Children — 28 (26-30)% 38 (36-40)%
Adolescent and young adults — 17 (16-17)% 29 (28-30)%
Older adults — 15 (14-16)% 26 (25-27)%
Leukemia-free survival .77
Children — 25 (19-31)% 34 (29-40)%
Adolescent and young adults — 16 (13-19)% 27 (24-30)%
Older adults — 15 (11-19)% 24 (21-26)%
Relapse .03
Children — 42 (36-49)% 40 (35-46)%
Adolescent and young adults — 29 (25-33)% 34 (31-37)%
Older adults — 25 (20-30)% 39 (37-42)%
Treatment-related mortality .05
Children — 33 (27-39)% 26 (21-31)%
Adolescent and young adults — 56 (51-60)% 39 (36-43)%
Older adults — 60 (54-66)% 37 (34-40)%
*Probability and 95% confidence intervals.
†P value for comparison in improvement in 5-year outcomes between the three age groups (two degrees of freedom).
Biol Blood Marrow Transplant 18:861-873, 2012 865AML Outcomes for AYAs after allo-HCTfrom 1998 to 2005, compared with 1980 to 1988, for all
age groups (Table 2, Figure 1A). Also, survival was in-
versely correlated with age for all three time periods; 5-
year OS for children, AYAs, and older adults undergo-
ing transplantations for AML in 1998 to 2005 were
64%, 43%, and 31%, respectively. Change in 5-year
OS for AYAs paralleled that for children and older
adults for the time periods studied (Table 2). In multi-
variate analyses of the MSD cohort, older age at HCT
was associated with increased risk of overall mortality.
Transplantation in a more recent time period, in gen-
eral, was associated with a lower risk of mortality
(Table 3). We also examined survival over time within
each age group using multivariate analyses (Table 4);
the AYA and older adult age groups improved the
most in OS over time, especially in the early posttrans-
plantation period for 1998 to 2005.
A similar trend was observed for LFS. Five-year
LFS rates improved over time for all age groups; better
LFS was seen for children than AYAs, who in turn had
better LFS than older adults (Table 2). Again, change
in LFS for AYAs paralleled that of children and older
adults. Multivariate analysis showed that older adults
had significantly worse LFS rates, whereas AYAs had
comparable LFS rates to those of children (Table 3).The time period of transplantation was not found to
be significantly associated with LFS, which was con-
firmed in multivariate analysis by age group (Table 4).
Cumulative incidence of TRM decreased over
time, especially among AYAs and older adults and
was again inversely related to patient age at time of
transplantation (Table 2). Multivariate analysis
showed there was a strong age correlation with relative
risk of TRM, with AYAs having twice the risk and
older adults having more than three times the risk of
dying from transplantation-related complications
than children (Table 3). Patients had a lower relative
risk of TRM in the 1989 to 1997 and 1998 to 2005
time periods than in the 1980 to 1988 time frame.
This was further confirmed in analyses for each age
group (Table 4); TRM improved from 1980 to 1988
to 1989 to 1997 for all three age groups. Early TRM
(\6 months posttransplantation) improved signifi-
cantly from 1989 to 1997 to 1998 to 2005 for AYAs
and older adults.
Multivariate analysis of all MSD showed differences
in relapse risks by age and time period (Table 3). In anal-
yseswithin each age group, whereas therewere no statis-
tically significant changes in relapse rates for children
andAYApatientsover the three timeperiods considered,
Figure 1. Trends over time for 5-year adjusted overall survival after HLA-identical sibling donor (A) and unrelated donor (B) hematopoietic cell trans-
plantation for AML. The edges of the box plots represent 95% confidence intervals.
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increased among older patients (Table 4). The relative
risk of early relapse among older patients who under-
went transplantation from 1998 to 2005 was 1.6 times
higher than those who underwent transplantation from
1989 to 1997 (hazard ratio [HR] 1.59, 95% confidence
interval [CI] 1.17-2.16, P5 .003) and three times higher
than those who underwent transplantation from 1980 to
1988 (HR, 3.01; 95% CI, 1.37-6.60; P5 .006).We found no significant interactions between age
group and time period for any of the endpoints stud-
ied. We observed no notable trends in outcome dis-
parities between the 15- to 25- and 26- to 40-year
age groups (Appendix Table 1). Although limited by
small numbers, unadjusted analyses for a subset of pa-
tients who had received myeloablative HCT for AML
in CR1 did not show a negative trend in survival for
AYAs (Appendix Table 2).
Table 3. Results of Multivariate Analyses forOverall Survival,
Leukemia-Free Survival, Relapse, and Treatment-Related
Mortality among Recipients of HLA-Identical Sibling Donor
Transplantation
Variable
Hazard
Ratio*
95% Confidence
Intervals P Value
Overall survival†
Age at transplantation, years
Children 1.0 — <.01‡
Adolescent and young adults 1.22 1.03-1.44 .02
Older adults 1.68 1.41-2.00 <.01
Year of transplantation
1980-1988 1.0 — <.01§
1989-1997 0.83 0.73-0.95 <.01
1998-2005 (<3 months after HCT) 0.55 0.44-0.70 <.01
1998-2005 ($3 months after HCT) 0.88 0.74-1.05 .15
Leukemia-free survivalk
Age at transplantation, years
Children 1.0 — <.01‡
Adolescent and young adults 1.14 0.97-1.34 .11
Older adults 1.47 1.24-1.75 <.01
Year of transplantation
1980-1988 1.0 — .06‡
1989-1997 0.87 0.77-1.00 .05
1998-2005 0.83 0.70-0.99 .02
Relapse¶
Age at transplantation, years
Children 1.0 — .02‡
Adolescent and young adults 0.76 0.62-0.93 <.01
Older adults 0.77 0.62-0.96 .02
Year of transplantation
1980-1988 1.0 — <.01§
1989-1997 1.10 0.90-1.34 .35
1998-2005 (<3 months after HCT) 1.66 1.24-2.22 <.01
1998-2005 ($3 months after HCT) 1.18 0.92-1.52 .20
Treatment-related mortality**
Age at transplantation, years
Children 1.0 — <.01‡
Adolescent and young adults 2.06 1.55-2.73 <.01
Older adults 3.40 2.53-4.56 <.01
Year of transplantation
1980-1988 1.0 — <.01§
1989-1997 0.65 0.55-0.77 <.01
1998-2005 (<6 months after HCT) 0.38 0.30-0.48 <.01
1998-2005 ($6 months after HCT) 0.64 0.47-0.85 <.01
*Hazard ratios refer to hazards of death or relapse.
†Other variables significantly associated with overall survival included
cytogenetic risk at diagnosis, disease status at transplantation, time
from diagnosis to transplantation, performance status score at trans-
plantation and patient gender (see also Appendix Table 3).
‡Overall P value, two degrees of freedom test.
§Overall P value, three degrees of freedom test.
¶Other variables significantly associated with relapse included cytoge-
netic risk at diagnosis, disease status at transplantation, time from diag-
nosis to transplantation, and performance status score at
transplantation (see also Appendix Table 3).
kOther variables significantly associated with leukemia-free survival
included gender, cytogenetic risk at diagnosis, disease status at trans-
plantation, time from diagnosis to transplantation, and performance sta-
tus score at transplantation (see also Appendix Table 3).
**Other variables significantly associated with treatment-related mor-
tality included disease status at transplantation, time from diagnosis to
transplantation and performance status score at transplantation (see
also Appendix Table 3).
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other than time period of transplantation and age
group that were significantly associated with outcomes
following MSD HCT.
Outcomes after Unrelated Donor HCT
Similar to recipients of MSD transplantations, sur-
vival for URD HCT recipients also improved signifi-
cantly over time (1989-1997 versus 1998-2005) and was
inversely related to age at transplantation (Table 2,
Figure 1B). Similar to sibling donor HCT, changes in
5-yearOS forAYAsparalleled those of children andolder
adults (Table 2). In multivariate analyses, older age at
time of HCTwas associated with increasing risk of over-
all mortality (Table 5). For the URD cohort, we also ob-
served a significant association between time period of
transplantation andOS after URDHCT, with mortality
risk improving for patients who underwent transplanta-
tion in themost recent timeperiod.Furthermore, analysis
by age group showed significant improvement in OS for
AYAs and older adults, but not for children, from1998 to
2005 when compared with 1989 to 1997 (Table 4).
Results similar to those for OS were observed for
LFS, with improved LFS for patients who underwent
transplantation from 1998 to 2005 compared with
1989 to 1997 (Table 2). In multivariate analyses that
included all URD HCT patients, children and those
with more recent transplantations (1998-2005) experi-
enced better LFS (Table 5). Analyses restricted by age
group showed that LFS had significantly improved in
the most recent time period for AYAs and older adults
but not for children (Table 4).
Cumulative incidence of TRM significantly de-
creased over time for all age groups (Table 2). Multi-
variate analyses showed that older age and
transplantation in an earlier time period were associ-
ated with higher risks of TRM (Table 5). Improve-
ments in TRM over time were seen in AYAs and
older adults but not in children (Table 4).
Cumulative incidence of relapse did not change
over the two time periods for children and AYAs but
increased for older adults (Table 2). This was also
observed on multivariate analyses by age group, where
older adults had a significantly higher risk of relapse if
they underwent transplantation in 1998-2005 com-
pared with 1989-1997 (HR, 1.70; 95% CI, 1.01-2.87;
P 5 .05) (Table 4).
As with the analysis of MSD HCT recipients, we
found no significant interactions between age group
and time period for any of the endpoints studied.
Exploratory analyses showed that the 15- to 25-year
age group had superior OS compared with the
26-40-year age group in both time periods studied
(Appendix Table 1). Again, unadjusted analyses in a
small subset of patients who had received myeloabla-
tive HCT for AML in CR1 did not show a negative
trend in survival for AYAs (Appendix Table 2).Appendix Table 4 shows hazard ratios for factors
other than time period of transplantation and age
group that were significantly associated with outcomes
following URD HCT.
Table 4. Contrasts between Time Periods of Transplantation for Each of the Three Age Groups after Matched Sibling Donor and
Unrelated Donor Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Children Adolescent and Young Adults Older Adults
MATCHED SIBLING DONOR TRANSPLANTATION
versus 1980-1988 versus 1989-1997 versus 1980-1988 versus 1989-1997 versus 1980-1988 versus 1989-1997
Overall survival
1989-1997 0.80 — 0.85* — 0.77 —
1998-2005 (<3 months) 0.77 0.96 0.40* 0.47* 0.54* 0.71*
1998-2005 ($3 months) 0.65 0.81 1.65 1.25 0.78 1.02
Leukemia-free survival
1989-1997 0.88 — 0.90 — 0.85 —
1998-2005 0.82 0.93 0.94 1.05 0.88 1.04
Relapse
1989-1997 1.06 — 1.08 — 1.89 —
1998-2005 (<3 months) 1.28 1.21 1.29 1.19 3.01* 1.59*
1998-2005 ($3 months) 0.60 0.57 1.35 1.25 2.06 1.08
Treatment-related mortality
1989-1997 0.48* — 0.80* — 0.63* —
1998-2005 (<6 months) 0.72 1.49 0.45* 0.57* 0.43* 0.67*
1998-2005 ($6 months) 0.95 1.96 0.94 1.12 0.68 1.08
UNRELATED DONOR TRANSPLANTATION
versus 1989-1997 versus 1989-1997 versus 1989-1997
Overall survival
1998-2005 1.06 0.59* 0.49*
Leukemia-free survival
1998-2005 1.06 0.63* 0.57*
Relapse
1998-2005 1.15 1.10 1.70*
Treatment-related mortality
1998-2005 0.93 0.40* 0.27*
The numbers in the table represent hazard ratios frommultivariate analysis adjusting for important patient and disease-related variables (hazard ratio of
>1.00 indicates increased hazards of death or relapse).
*P < .05.
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Our study shows that survival for AYAs after allo-
geneic HCT for AML using either MSD or URD has
improved over time, and unlike survival rates of can-
cer in general, improvements in survival for AYAs af-
ter transplantation have not necessarily lagged behind
those for children and older adults. Children have the
best survival, followed by AYAs, and older adults have
the worst survival rates after allogeneic HCT for
AML.
Several factors have been implicated in the lack of
progress against cancer in AYAs [1-4]. These include
underrecognition of cancer risk and adverse cancer
outcomes in this population, and restricted or
delayed access to care given that AYAs have the
highest uninsured rate of any age group in the
country. AYAs have exceedingly low participation
rates in cancer clinical trials, which has resulted in
a poor understanding of the patient and tumor
biology that distinguishes cancers in this age group
[1-3]. Although AYAs with cancer, in general, have
not seen the same improvement in survival compared
with their younger and older counterparts [1-4], our
study did not find age-related disparities in outcomes
improvement in recent years. Children who already
had better outcomes than AYAs and older patients in
the earliest years of the study maintained but did not
improve their outcomes over time, whereas bothAYAs and older adults are doing better in recent years
but still not achieving the success seen in children.
Surveillance Epidemiology and End Results data
show similar survival trends among patients with
AML [17]. Five-year survival rates for AML decline
with advancing age. In analyses that evaluated 5-year
survival rates for AML by age according to era (four
equal 6-year intervals from 1975 to 1998), survival re-
mained inversely correlated with age and improve-
ments in survival in all age categories occurred over
time. However, during the late 1980s and 1990s, im-
provement in AML survival in those \30 years of
age was negligible and considerably less than in older
patients. We observed a similar plateau in outcomes
in children undergoing HCT for AML.
Similar to another CIBMTR analysis [7], improve-
ment in survival for all age groups has largely been
driven by decreasing risks of TRM after both MSD
and URD HCT. Rates of relapse did not improve
over time, and in fact, worsened among older adults.
This likely reflects changes in transplantation practices
over time. Improvements in understanding of AML
prognostic factors andHCT techniques and supportive
carehave allowed earlier transplantation inhigh-risk pa-
tients more recently. Although data on cytogenetic risk
were missing for a large proportion of patients who un-
derwent transplantation in the earlier time periods,
more patients underwent transplantation in 1998 to
Table 5. Results ofMultivariate Analyses forOverall Survival,
Leukemia-FreeSurvival, Relapse, andTreatment-RelatedMor-
tality among Recipients of Unrelated Donor Transplantation
Variable
Hazard
Ratio*
95% Confidence
Intervals P Value
Overall survival†
Age at transplantation, years
Children 1.0 — <.01‡
Adolescent and young adults 1.33 1.18-1.50 <.01
Older adults 1.43 1.26-1.62 <.01
Year of transplantation
1989-1997 1.0 — <.01
1998-2005 0.74 0.67-0.81
Leukemia-free survival§
Age at transplantation, years
Children 1.0 — <.01‡
Adolescent and young adults 1.22 1.08-1.38 <.01
Older adults 1.28 1.14-1.45 <.01
Year of transplantation
1989-1997 1.0 — <.01
1998-2005 0.80 0.73-0.87
Relapsek
Age at transplantation, years
Children 1.0 — .03‡
Adolescent and young adults 0.80 0.68-0.95 .01
Older adults 0.90 0.76-1.05 .18
Year of transplant
1989-1997 1.0 — .10
1998-2005 1.13 0.98-1.30
Treatment-related mortality¶
Age at transplantation, years
Children 1.0 — <.01‡
Adolescent and young adults 1.83 1.53-2.18 <.01
Older adults 1.90 1.58-2.29 <.01
Year of transplantation
1989-1997 1.0 — <.01
1998-2005 0.57 0.51-0.64
*Hazard ratios refer to hazards of death or relapse.
†Other variables significantly associated with overall survival included
race/ethnicity, cytogenetic risk at diagnosis, disease status at transplan-
tation, time from diagnosis to transplantation, and performance status
score at transplantation (see also Appendix Table 4).
‡Overall P value, two degrees of freedom test.
§Other variables significantly associated with leukemia-free survival in-
cluded cytogenetic risk at diagnosis, disease status at transplantation,
time from diagnosis to transplantation, and performance status score
at transplantation (see also Appendix Table 4).
¶Other variables significantly associated with treatment-related mortal-
ity included race/ethnicity, disease status at transplantation and perfor-
mance status score at transplantation (also see Appendix Table 4).
kOther variables significantly associated with relapse included cytoge-
netic risk at diagnosis, disease status at transplantation, time from
diagnosis to transplantation, and performance status score at trans-
plantation (see also Appendix Table 4).
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inherently at higher risk for AML relapse, and the num-
ber of older patients who underwent transplantation in
the most recent time period increased substantially be-
cause of the availability ofRIC/NMAregimens.Relapse
continues tobe amajor reason for treatment failure after
allogeneic HCT for AML, and more research and ad-
vancement in this area is still needed tooptimize survival
after allogeneic HCT for all age groups [18].
Our study has the usual limitations of a retrospec-
tive cohort study using registry-level data. Our find-
ings are specific to allogeneic HCT and AML and
may not be generalizable to other malignancies preva-lent among AYAs that are treated with HCT. Also,
there may be a selection bias at the level of centers in
offering transplantation as therapy to patients who
were more likely to have favorable outcomes. For in-
stance, patients with inadequate caregiver support
and financial resources and those who were noncom-
pliant with therapy may not have been referred for or
offered allogeneic HCT as a treatment option for their
leukemia. AYAs are more likely to encounter access
barriers than other age groups [1,2]. Our study did
not address issues related to access to allogeneic
HCT for AYAs.
Although we found no disparities in survival
improvement over time, other issues remain in deter-
mining what causes the disparity in outcomes between
AYAs and the other age groups. These include the
availability of AYA-appropriate patient educational
materials and resources, appropriate methods of
patient communication, and AYA-specific posttrans-
plantation quality of life, and transition to survivor-
ship. AYAs who develop chronic graft-versus-host
disease face a chronic health condition that can be as-
sociated with significant long-term morbidity and
quality-of-life impairment, and they may need age-
specific treatments and supportive care.
In conclusion, our study shows that improvements
in survival among AYAs undergoing allogeneic HCT
for AML parallel those of other age groups.ACKNOWLEDGMENTS
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or any other agency of the US Government.Appendix Table 1. Unadjusted Probability of Overall Sur-
vival and Leukemia-Free Survival and Cumulative Incidences
of Relapse and Treatment-Related Mortality at 5 Years after
Transplantation for Patients Aged 15 to 25 Years and 26 to
40 Years
Outcome
Age 15-25 years Age 26-40 years
P ValueN
Probability
(95% CI) N
Probability
(95% CI)
Matched sibling
donor HCT
Overall survival
1980-1988 176 42 (35-50)% 286 34 (29-40)% .08
1989-1997 194 46 (38-53)% 410 37 (32-42)% .06
1998-2005 77 47 (34-61)% 144 41 (32-49)% .41
Leukemia-free survival
1980-1988 173 40 (33-48)% 281 32 (27-38)% .09
1989-1997 193 43 (35-50)% 402 33 (29-38)% .04
1998-2005 76 46 (33-60)% 140 39 (31-48)% .39
Relapse
1980-1988 173 33 (26-40)% 281 43 (37-49)% .03
1989-1997 193 34 (27-41)% 402 34 (29-39)% .94
1998-2005 76 40 (27-53)% 140 37 (29-46)% .75
Treatment-related
mortality
1980-1988 173 27 (21-34)% 281 25 (20-30)% .61
1989-1997 193 24 (18-30)% 402 33 (28-38)% .02
1998-2005 76 14 (6-23)% 140 23 (16-31)% .09
Unrelated donor HCT
Overall survival
1989-1997 189 22 (16-28)% 316 13 (10-17)% .02
1998-2005 381 33 (28-38)% 535 26 (22-30)% .04
Leukemia-free survival
1989-1997 186 21 (15-27)% 314 13 (9-17)% .02
1998-2005 377 30 (25-35)% 522 25 (21-29)% .13
Relapse
1989-1997 186 29 (23-36)% 314 28 (24-33)% .88
1998-2005 377 34 (29-39)% 522 34 (30-38)% .92
Treatment-related
mortality
1989-1997 186 50 (43-57)% 314 59 (54-64)% .05
1998-2005 377 36 (31-41)% 522 41 (37-46)% .12REFERENCES
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Appendix Table 2. Unadjusted Outcomes at 5 Years after Transplantation in the Subset of Children, AYAs, andOlder Adults with
AML in CR1 Who Received a Myeloablative HCT
Outcome
1980-1988* 1989-1997* 1998-2005*
P ValueN N N
Matched sibling donor HCT
Overall survival
Children 68 60 (48-72)% 120 58 (49-67)% 56 69 (55-81)% .41
Adolescent and young adults 262 49 (43-55)% 299 57 (52-63)% 96 52 (42-63)% .16
Older adults 23 35 (17-55)% 152 35 (28-43)% 146 47 (38-56)% .13
Leukemia-free survival
Children 67 61 (49-72)% 119 54 (44-63)% 55 65 (51-78)% .33
Adolescent and young adults 256 46 (40-52)% 297 53 (47-58)% 95 51 (41-61)% .32
Older adults 22 32 (14-52)% 150 35 (28-43)% 144 46 (37-55)% .16
Relapse
Children 67 15 (7-24)% 119 38 (30-47)% 55 21 (11-33)% <.01
Adolescent and young adults 256 17 (13-22)% 297 20 (16-25)% 95 28 (20-38)% .09
Older adults 22 14 (3-31)% 150 22 (16-29)% 144 25 (18-32)% .40
Treatment-related mortality
Children 67 24 (15-35)% 119 8 (4-14)% 55 14 (6-26)% .02
Adolescent and young adults 256 37 (31-43)% 297 27 (22-32)% 95 20 (13-29)% <.01
Older adults 22 55 (34-74)% 150 43 (35-51)% 144 29 (22-37)% .02
Unrelated donor HCT
Overall survival
Children — 44 36 (23-51)% 91 34 (24-45)% .81
Adolescent and young adults — 93 22 (15-31)% 235 41 (34-48)% <.01
Older adults — 45 22 (11-35)% 261 34 (28-41)% .09
Leukemia-free survival
Children — 44 32 (19-46)% 91 35 (25-45)% .71
Adolescent and young adults — 92 22 (14-31)% 231 40 (33-46)% <.01
Older adults — 45 22 (11-35)% 257 34 (28-41)% .09
Relapse
Children — 44 30 (17-44)% 91 35 (25-45)% .53
Adolescent and young adults — 92 12 (6-19)% 231 24 (19-30)% <.01
Older adults — 45 16 (7-27)% 257 27 (21-33)% .07
Treatment-related mortality
Children — 44 39 (25-53)% 91 30 (21-40)% .33
Adolescent and young adults — 92 66 (56-76)% 231 36 (30-43)% <.01
Older adults — 45 62 (48-76)% 257 39 (33-45)% <.01
*Probability and 95% confidence intervals.
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Appendix Table 3. Factors Other Than Year of Transplanta-
tion and Age Group That Were Significantly Associated with
Overall Survival, Leukemia-Free Survival, Relapse, and
Treatment-Related Mortality among Recipients of HLA-
Identical Sibling Donor Transplantation
Variable
Hazard
Ratioa
95% Confidence
Intervals P Value
Overall survival
Cytogenetic risk
Good 1.0 <.01
Intermediate 1.28 1.02-1.60 .04
Poor 1.79 1.39-2.31 <.01
Unknown 1.48 1.17-1.87 <.01
Disease status at transplantation
First complete remission 1.0 <.01
Second complete remission 1.49 1.24-1.78 <.01
Other 2.14 1.90-2.40 <.01
Unknown 4.56 2.26-9.23 <.01
Time from diagnosis to
transplantation
<6 months 1.00 <.01
6-12 months 1.24 1.09-1.40 <.01
>12 months 0.95 0.81-1.10 .46
Unknown 0.52 0.07-3.75 .52
KPS score at transplantation
<90 1.0 <.01
$90 0.74 0.66-0.82 <.01
Unknown 0.74 0.55-0.99 .05
Gender
Male 1.0 <.01
Female 0.87 0.79-0.96
Leukemia-free survival
Cytogenetic risk
Good 1.0 <.01
Intermediate 1.31 1.05-1.64 .02
Poor 1.89 1.47-2.43 <.01
Unknown 1.46 1.15-1.84 <.01
Disease status at transplantation
First complete remission 1.0 <.01
Second complete remission 1.58 1.32-1.88 <.01
Other 2.20 1.96-2.47 <.01
Unknown 4.03 1.90-8.53 <.01
Time from diagnosis to
transplantation
<6 months 1.0 <.01
6-12 months 1.23 1.08-1.39 <.01
>12 months 0.90 0.78-1.05 .18
Unknown 0.40 0.06-2.90 .37
KPS score at transplantation
<90 1.0 <.01
$90 0.76 0.69-0.84 <.01
Unknown 0.82 0.61-1.10 .18
Gender
Male 1.0 <.01
Female 0.86 0.78-0.95
Relapse
Cytogenetic risk
Good 1.0 <.01
Intermediate 1.78 1.25-2.53 <.01
Poor 2.86 1.96-4.16 <.01
Unknown 1.70 1.17-2.45 <.01
Disease status at transplantation
First complete remission 1.00 <.01
Second complete remission 2.23 1.72-2.86 <.01
Other 3.40 2.89-3.99 <.01
Unknown 4.28 1.36-13.45 .01
Time from diagnosis to
transplantation
<6 months 1.00 <.01
6-12 months 1.17 0.99-1.39 .07
>12 months 0.58 0.47-0.72 <.01
KPS score at transplantation
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Appendix Table 3. (Continued )
Variable
Hazard
Ratioa
95% Confidence
Intervals P Value
<90 1.00 <.01
$90 0.73 0.63-0.84 <.01
Unknown 0.90 0.61-1.33 .59
Treatment-related mortality
Disease status at transplantation
First complete remission 1.0 <.01
Second complete remission 1.14 0.89-1.45 .31
Other 1.41 1.19-1.67 <.01
Unknown 4.01 1.48-10.84 <.01
Time from diagnosis to
transplantation
<6 months 1.0 <.01
6-12 months 1.29 1.08-1.54 <.01
>12 months 1.35 1.09-1.66 <.01
Unknown 2.75 0.38-19.98 .32
KPS score at transplantation
<90 1.0 <.01
$90 0.79 0.68-0.92 <.01
Unknown 0.77 0.49-1.20 .25
aHazard ratios refer to hazards of death or relapse.
872 Biol Blood Marrow Transplant 18:861-873, 2012N. S. Majhail et al.
Appendix Table 4. Factors Other Than Year of Transplanta-
tion and Age Group That Were Significantly Associated with
Overall Survival, Leukemia-Free Survival, Relapse, and
Treatment-Related Mortality among Recipients of Unrelated
Donor Transplantation
Variable
Hazard
Ratioa
95% Confidence
Intervals P Value
Overall survival
Cytogenetic risk
Good 1.0 <.01
Intermediate 1.17 0.97-1.41 .10
Poor 1.48 1.21-1.80 <.01
Unknown 1.35 1.11-1.63 <.01
Disease status at transplantation
First complete remission 1.0 <.01
Second complete remission 1.18 1.04-1.35 .01
Other 1.82 1.65-2.01 <.01
Unknown 1.65 0.86-3.17 .13
Time from diagnosis to
transplantation
<6 months 1.0 <.01
6-12 months 1.12 1.02-1.24 .02
>12 months 0.87 0.77-0.97 .01
Unknown 0.63 0.27-1.51 .30
KPS score at transplantation
<90 1.0 <.01
$90 0.74 0.68-0.80 <.01
Unknown 0.69 0.59-0.81 <.01
Ethnicity/race
White 1.0 <.01
Black 1.50 1.25-1.80 <.01
Asian/Pacific-Islander 1.06 0.78-1.43 .73
Hispanic 1.04 0.87-1.25 .66
Other 1.01 0.63-1.63 .97
Leukemia-free survival
Cytogenetic risk
Good 1.0 <.01
Intermediate 1.19 0.99-1.42 .07
Poor 1.50 1.23-1.82 <.01
Unknown 1.34 1.11-1.62 <.01
Disease status at transplantation
First complete remission 1.0 <.01
Second complete remission 1.22 1.07-1.39 <.01
Other 1.99 1.80-2.19 <.01
Unknown 1.45 0.74-2.89 .28
Time from diagnosis to
transplantation
<6 months 1.0 <.01
6-12 months 1.11 1.01-1.22 .03
>12 months 0.83 0.74-0.92 <.01
Unknown 0.66 0.27-1.62 .36
KPS score at transplantation
<90 1.0 <.01
$90 0.74 0.68-0.80 <.01
Unknown 0.74 0.63-0.86 <.01
Relapse
Cytogenetic risk
Good 1.0 <.01
Intermediate 1.58 1.15-2.16 <.01
Poor 2.04 1.47-2.84 <.01
Unknown 1.73 1.25-2.39 <.01
Disease status at transplantation
First complete remission 1.0 <.01
Second complete remission 1.39 1.13-1.70 <.01
Other 3.17 2.74-3.66 <.01
Unknown 1.55 0.59-4.08 .40
Time from diagnosis to
transplantation
<6 months 1.0 <.01
6-12 months 1.08 0.95-1.23 .26
>12 months 0.59 0.50-0.69 <.01
Unknown 1.01 0.32-3.18 .98
KPS score at transplantation
(Continued )
Appendix Table 4. (Continued )
Variable
Hazard
Ratioa
95% Confidence
Intervals P Value
<90 1.0 <.01
$90 0.68 0.60-0.76 <.01
Unknown 0.86 0.71-1.05 .13
Treatment-related mortality
Disease status at transplantation
First complete remission 1.0 <.01
Second complete remission 1.07 0.93-1.24 .34
Other 1.32 1.16-1.50 <.01
Unknown 0.91 0.43-1.93 .80
KPS score at transplantation
<90 1.0 <.01
$90 0.79 0.71-0.89 <.01
Unknown 0.58 0.45-0.74 <.01
Ethnicity/race
White 1.0 <.01
Black 1.68 1.33-2.13 <.01
Asian/Pacific-Islander 1.22 0.82-1,81 .33
Hispanic 1.13 0.89-1.43 .31
Other 0.99 0.45-2.00 .99
KPS indicates Karnofsky Performance Status.
aHazard ratios refer to hazards of death or relapse.
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